Entering the European market offers significant strategic value. However, success under the MDR requires more than adapting an existing FDA or NMPA submission.
The MDR introduces a lifecycle-driven regulatory model in which intended purpose, clinical evidence, State of the Art (SOTA), regulatory requirements, and benefit–risk justification must form one coherent and continuously maintained system.
In this blog, we explain why clinical strategy, not data, is often the true bottleneck for EU market access.
The Real Challenge Is Alignment, Not Data
Challenges encountered during EU market entry are often not solely related to the absence of clinical data. More frequently, the issue lies in aligning existing data, regulatory positioning, and clinical strategy with EU expectations.
In practice, manufacturers may encounter:
- Clinical evidence that does not fully support intended use and claims
- Regulatory elements, such as intended purpose or classification, that are not aligned with the available evidence
- Equivalence strategies that require further justification under MDR expectations
- Clinical data that requires additional context to demonstrate relevance to EU populations
These situations can lead to additional questions during Notified Body review, requests for further clarification or evidence, and potential impact on timelines.
Regulatory and Clinical Must Work as One System
A key contributing factor is that regulatory and clinical decisions are not always sufficiently aligned from the outset. Under the MDR, regulatory decisions, including intended purpose, claims, risk classification, and conformity assessment route, directly determine the evidence required.
Clinical strategy must be aligned with each of these elements from the very beginning.
Successful EU market entry depends on developing regulatory and clinical strategy in an integrated way and maintaining that alignment throughout the device lifecycle.
QbD Group supports this approach by combining regulatory expertise, clinical strategy, and lifecycle management into one coherent framework. Through early gap assessments, alignment of intended purpose and evidence strategy, and targeted data generation, manufacturers can make more effective use of existing data and better anticipate EU requirements.
Looking Ahead: The Proposed MDR Revision
The European Commission's December 2025 proposal to amend the MDR introduces a shift toward a more risk-based, data-driven framework.
Key proposed changes include:
- Removing the requirement for formal contracts to access competitor technical data if equivalence can be scientifically demonstrated through public information
- Formal recognition of modern evidence sources such as Real-World Evidence (RWE), in silico methodologies, and broader scientific literature
- Removing mandatory clinical investigations for certain Class IIa implantable devices
- Introducing adapted pathways for Well-Established Technologies (WET)
- Allowing increased reliance on regulatory decisions from other jurisdictions
Beyond clinical changes, the proposal also aims to streamline regulatory processes, reduce administrative burden, strengthen digitalization, and improve coordination across authorities.
A new joint scientific and regulatory advice procedure would allow manufacturers to validate their clinical strategies early with expert panels and Notified Bodies, enabling a more predictable and cost-effective pathway to market.
With a structured and integrated approach, EU regulatory complexity can be managed more predictably, supporting a more efficient and sustainable path to market.
Looking to Go Deeper?
Understanding EU market access requires more than generating data, it requires aligning clinical strategy, regulatory positioning, and lifecycle management from the start.
👉 Download the QbD Group whitepaper “Home Market Approval ≠ EU Readiness” to explore the key gaps and how to address them.
关于作者
PhD Physics, MSc Medical Physics · Business Unit Manager RA MD
Anne-Sophie is a Regulatory Affairs leader with over two decades of experience in medical physics, diagnostic imaging, and medical device regulation. She supports clients navigating EU MDR, FDA, and international regulatory frameworks.
关于作者
Business Unit Manager Medical Affairs
12 years of experience in the medical device field. Expert in clinical evidence and medical writing for Class I to Class III devices, including MDSW and AI-driven MDSW, as well as safety management in clinical investigations.
Watch the Webinar: Entering the European MedTech Market
Why one approval doesn't fit all — discover where FDA and NMPA logic breaks down under EU MDR, and how to build a defensible market-entry strategy.
Watch the webinar订阅生命科学领域的最新动态
专家观点直达您的收件箱——选择您的兴趣。
绝无垃圾邮件。随时取消订阅。
